Hobbs Group Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$405K Sell
1,609
-20
-1% -$4.3K 0.11% 123
2026
Q1
$354K Sell
1,629
-1,785
-52% -$396K 0.11% 129
2025
Q4
$780K Buy
3,414
+41
+1% +$9.34K 0.24% 69
2025
Q3
$781K Sell
3,373
-14
-0.4% -$2.85K 0.24% 70
2025
Q2
$629K Sell
3,387
-496
-13% -$92.2K 0.22% 81
2025
Q1
$814K Sell
3,883
-245
-6% -$47.6K 0.31% 67
2024
Q4
$734K Buy
4,128
+260
+7% +$47.8K 0.28% 73
2024
Q3
$764K Buy
3,868
+58
+2% +$10.8K 0.27% 66
2024
Q2
$653K Buy
+3,810
New +$631K 0.25% 72
2023
Q4
$527K Buy
+3,403
New +$496K 0.24% 68

Other funds holding ABBV

Hobbs Group Advisors's ABBV Position: Q2 2026 in Review

Hobbs Group Advisors reduced its AbbVie (ABBV) stake by 1.2% in Q2 2026, selling an estimated $4.3K and leaving 1,609 shares worth $405K. The position accounts for 0.11% of the portfolio, ranked #123.

Hobbs Group Advisors first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $814K in Q1 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Hobbs Group Advisors held 1,609 shares of AbbVie worth $405K as of Q2 2026.
  • Hobbs Group Advisors sold 20 AbbVie shares in Q2 2026, an estimated $4.3K.
  • AbbVie made up 0.11% of Hobbs Group Advisors's portfolio in Q2 2026, its #123 holding.
  • Hobbs Group Advisors first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
  • Hobbs Group Advisors's AbbVie position peaked at $814K in Q1 2025.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hobbs Group Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.